登录/注册
安卓版下载
logo
  • 时政综合
  • 商业财经
  • 文学小说
  • 摄影数码
  • 学生必读
  • 家庭养生
  • 旅游美食
  • 人文科普
  • 文摘文萃
  • 艺术收藏
  • 农业乡村
  • 文化综合
  • 职场理财
  • 娱乐时尚
  • 学术
  • 军事
  • 汽车
  • 环时

2019年2期

Cancer Drug Resistance

上一期 下一期 浏览往期
Review
  • Drug resistance and combating drug resistance in cancer
  • Emerging targets in cancer drug resistance
  • Mechanism of resistance to immune checkpoint inhibitors
  • Molecular mechanisms of enzalutamide resistance in prostate cancer
  • New insights into acquired endocrine resistance of breast cancer
  • Overcome cancer drug resistance by targeting epigenetic modifications of centrosome
  • Pharmacogenetic and pharmacogenomic discovery strategies
  • Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
  • Pharmacogenetics of thiopurines
  • Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
  • Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
  • The epigenome in pediatric acute lymphoblastic leukemia:drug resistance and therapeutic opportunities
  • The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors
Perspective
  • Perspective:plasticity,the enemy of the good
Opinion
  • Glutaminase inhibition in renal cell carcinoma therapy
Commentary
  • Resistance to ERK1/2 pathway inhibitors; sweet spots,fitness deficits and drug addiction
  • Daunorubicin can eliminate iPS-derived cancer stem cells via lCAD/CAD-independent DNA fragmentation

关于参考网